Systemic and ocular complications of sulfur mustard: A panoramic review

Toxin Reviews

Volumn 28, Issue 1, 2009, Pages 14-23

  Ghasemi, Hassan ^a   Ghazanfari, Tooba ^a   Yaraee, Roya ^a   Soroush, Mohammad Reza ^b   Ghassemi Broumand, Mohammad ^c   Poorfarzam, Shahriar ^a   Babaei, Mahmoud ^d   Javadi, Mohammad Ali ^d   Owlia, Parviz ^a   Amiri, Sara ^a   Hassan, Zuhair Mohammad ^e   Faghihzadeh, Soghrat ^e  

^a SHAHED UNIVERSITY   (Iran)

^b JANBAZAN MEDICAL AND ENGINEERING RESEARCH CENTER JMERC   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e TARBIAT MODARES UNIVERSITY   (Iran)

Author keywords

Eye; Ocular; Review; Sulfur mustard; Systemic; War victim

Indexed keywords

ACETYLCYSTEINE; ANTIINFLAMMATORY AGENT; ATROPINE; BICARBONATE; BORIC ACID; CETIRIZINE; CHLORINE DERIVATIVE; DNA; DOXEPIN; DOXYCYCLINE; HYDROXYZINE; IMMUNOGLOBULIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MINERAL OIL; MUSTARD GAS; MYDRIATIC AGENT; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NITROFURAL; OLIVE OIL; PERFLUORO COMPOUND; POLITEF; PROTEINASE INHIBITOR; STEROID; SULFADIAZINE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ACCIDENTAL INJURY; ACUTE TOXICITY; ARTICLE; BLINDNESS; CHEMICAL BURN; CHEMICAL WARFARE; CHRONIC TOXICITY; CLINICAL TRIAL; CORNEA NEOVASCULARIZATION; EYE DISEASE; EYE LAVAGE; EYE TOXICITY; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HISTORY; HUMAN; IMMUNE DEFICIENCY; INTOXICATION; KERATITIS; PATHOPHYSIOLOGY; PENETRATING KERATOPLASTY; PROTECTIVE CLOTHING; PRURITUS; RESPIRATORY FAILURE; SKIN DEFECT; TERATOGENICITY; TERRORISM;

EID: 70350569183     PISSN: 15569543     EISSN: 15569551     Source Type: Journal    
DOI: 10.1080/15569540802689279     Document Type: Article

References (106)

1. Aasted A, Darre E, Wulf HC. (1987). Mustard gas: clinical, toxicological, and mutagenic aspects based on modern experience. Ann Plast Surg 19:330-333.
2. Amir A, Turetz J, Chapman S, Fishbeine E, Meshulam J, Sahar R, Liani H, Gilat E, Frishman G, Kadar T. (2000). Beneficial effects of topical anti-inflammatory drugs against sulfur mustard-induced ocular lesions in rabbits. J Appl Toxicol 20(suppl 1):S109-S114.
3. Arroyo CM, Schafer RJ, Kurt EM, Broomfield CA, Carmichael AJ. (2000). Response of normal human keratinocytes to sulfur mustard: cytokine release. J Appl Toxicol 20:S63-S72.
4. Assennato G, Ambrosi F, Sivo D. (1997). [Possible long-term effects on the respiratory system of exposure to yperite of fishermen]. Med Lav 88:148-154.
5. Azizi F, Amini M, Arbab P. (1993). Time course of changes in free thyroid indices, rT3, TSH, cortisol and ACTH following exposure to sulfur mustard. Exp Clin Endocrinol 101:303-306.
6. Azizi F, Keshavarz A, Roshanzamir F, Nafarabadi M. (1995). Reproductive function in men following exposure to chemical warfare with sulfur mustard. Med War 11:34-44.
7. Bakhtavar K, Sedighi N, Moradi Z. (2008). Inspiratory and expiratory high-resolution computed tomography (HRCT) in patients with chemical warfare agents exposure. Inhal Toxicol 20:507-511.
8. Balali-Mood M, Hefazi M. (2005). The pharmacology, toxicology, and medical treatment of sulfur mustard poisoning. Fundam Clin Pharmacol 19:297-315.
9. Balali-Mood M, Hefazi M. (2006). Comparison of early and late toxic effects of sulfur mustard in Iranian veterans. Basic Clin Pharmacol Toxicol 99:273-282.
10. Bignold LP. (2006). Alkylating agents and DNA polymerases. Anticancer Res 26:1327-1336.
11. Blaha M, Bowers W, Kohl, JJr., DuBose D, Walker J, Alkhyyat A, Wong G. (2000). Effects of CEES on inflammatory mediators, heat shock protein 70A, histology and ultrastructure in two skin models. J Appl Toxicol 20:S101-S108.
12. Bobb AJ, Arfsten DP, Jederberg WW. (2005). N-acetyl-L-Cysteine as prophylaxis against sulfur mustard. Mil Med 170:52-56.
13. Borak J, Sidell FR. (1992). Agents of chemical warfare: sulfur mustard. Ann Emerg Med 21:303-308.
14. Bullman T, Kang H. (2000). A fifty year mortality follow-up study of veterans exposed to low level chemical warfare agent, mustard gas. Ann Epidemiol 10:333-338.
15. Buscher H. (1944). Green and Yellow Cross: Special Pathology and Terapy of Injuries Caused by the Chemical War Materials of the Green Cross Group (Phosgene and Diphosgene) and of the Yellow Cross Group (Mustard Gas and Lewisite). Cincinnati, OH: Kettering Laboratory.
16. Calvet JH, Planus E, Rouet P, Pezet S, Levame M, Lafuma C, Harf A, D'Ortho MP. (1999). Matrix metalloproteinase gelatinases in sulfur mustard-induced acute airway injury in guinea pigs. Am J Physiol 276:L754-L762.
17. Dacre JC, Goldman M. (1996). Toxicology and pharmacology of the chemical warfare agent sulfur mustard. Pharmacol Rev 48:289-326.
18. Demetrius E, Hinsley D, Rice P. (2002). Chemical weapons regular review. BMJ 2-9:332-335.
19. DH Department of Health. (2007). Acute management of mustard gas injuries of the eye. 3-11. DH Department of Health.
20. Drasch G, Kretschmer E, Kauert G, von Meyer L. (1987). Concentrations of mustard gas [bis(2-chloroethyl)sulfide] in the tissues of a victim of a vesicant exposure. J Forensic Sci 32:1788-1793.
21. Dua HS, Saini JS, Zuara-Blanco A, Gupta P. (2000). Limbal stem cell deficiency: concept, aetiology, clinical presentation, diagnosis and management. Indian J Ophthalmol 48:83-92.
22. Eisenkraft A, Luria S, Robenshtok E, Hourvitz A. (2003). [Using thalidomide against pathological neovascularization]. Harefuah 142: 212-216, 237.
23. Etezad-Razavi M, Mahmoudi M, Hefazi M, Balali-Mood M. (2006). Delayed ocular complications of mustard gas poisoning and the relationship with respiratory and cutaneous complications. Clin Experiment Ophthalmol 34:342-346.
24. Garner JP. (2003). Some recollections of Porton in World War 1. Commentary. J R Army Med Corps 149:138-141.
25. Gee CJ, Bonkowske J, Kurup SK. (2008). Visual disability in selected acts of terror, warfare, and natural disasters of the last 25 years: a concise narrative review. Am J Disaster Med 3:25-30.
26. Geraci MJ. (2008). Mustard gas: imminent danger or eminent threat? Ann Pharmacother 42:237-246.
27. Ghanei M, Vosoghi AA. (2002). An epidemiologic study to screen for chronic myelocytic leukemia in war victims exposed to mustard gas. Environ Health Perspect 110:519-521.
28. Ghasemi H, Ghzanfari T, Babaei M, Soroush M, Yaraee R, Ghassemi-Broumand M, Javadi MA, Foroutan A, Vaez Mahdavi MR, Shams J, Pourfarzam S, Moaiedmohseni S, Jalali Nadoushan MR, Owlia P, Panahi Y, Hassan Z, Faghihzadeh S. (2008). Long-term ocular complications of Sulfur mustard in the civilian victims of Sardasht, Iran. Cutaneous and Ocular Toxicology 27 (4) 317-326.
29. Ghasemi-Broumand M, Karami G, Pourfarzam S, Emadi S, Ghasemi H. (2007). Delayed ophthalmic, respiratory, cutaneous and psychiatric complications of chemical warfare agents on 479 war veterans. Daneshvar Medicine 70:81-92. In Persian.
30. Ghazanfari T, Faghihzadeh S, Aragizadeh H, Soroush MR, Yaraee R, Hassan ZM, et al., (2009) Sardasht-Iran Cohort Study of Chemical Warfare Victims: Design and Methods, Arch Iranian Med 12 (1): 5-14.
31. Ghotbi L, Hassan Z. (2002). The immunostatus of natural killer cells in people exposed to sulfur mustard. Int Immunopharmacol 2:981-985.
32. Godwin ED. (1942). War gas injuries of the eye. Cal West Med 57:299-301.
33. Goozner B, Lutwick LI, Bourke E. (2002). Chemical terrorism: a primer for 2002. J Assoc Acad Minor Phys 13:14-18.
34. Graham JS, Chilcot RP, Rice P, Milner SM, Hurst CG, Maliner BI. (2005). Wound healing of cutaneous sulfur mustard injuries: strategies for the development of improved therapies. J Burns Wounds 4:e1.
35. Grando SA. (2003). Mucocutaneous cholinergic system is targeted in mustard-induced vesication. Life Sci 72:2135-2144.
36. Gross CL, Innace JK, Hovatter RC, Meier HL, Smith WJ. (1993). Biochemical manipulation of intracellular glutathione levels infuences cytotoxicity to isolated human lymphocytes by sulfur mustard. Cell Biol Toxicol 9:259-267.
37. Guignabert C, Taysse L, Calvet JH, Planus E, Delamanche S, Galiacy S, d'Ortho MP. (2005). Effect of doxycycline on sulfur mustard-induced respiratory lesions in guinea pigs. Am J Physiol Lung Cell Mol Physiol 289:L67-L74.
38. Hassan ZM, Ebtekar M, Ghanei M, Taghikhani M, Noori Daloii MR, Ghazanfari T. (2006). Immunobiological consequences of sulfur mustard contamination. Iran J Allergy Asthma Immunol 5:101-108.
39. Hay A. (2000). Old dogs or new tricks: chemical warfare at the millennium. Med Confl Surviv 16:37-41.
40. Iyriboz Y. (2004). A recent exposure to mustard gas in the United States: clinical findings of a cohort (n = 247) 6 years after exposure. Med Gen Med 6:4.
41. Jankowski MK, Schnurr PP, Adams GA, Green BL, Ford JD, Friedman MJ. (2004). A mediational model of PTSD in World War II veterans exposed to mustard gas. J Trauma Stress 17:303-310.
42. Javadi MA, Yazdani S, Kanavi MR, Mohammadpour M, Baradaran-Rafiee A, Jafarinasab MR, Einollahi B, Karimian F, Zare M, Naderi M, Rabei HM. (2007). Long-term outcomes of penetrating keratoplasty in chronic and delayed mustard gas keratitis. Cornea 26:1074-1078.
43. Javadi MA, Yazdani S, Sajjadi H, Jadidi K, Karimian F, Einollahi B, Ja'farinasab MR, Zare M. (2005). Chronic and delayed-onset mustard gas keratitis: report of 48 patients and review of literature. Ophthalmology 112:617-625.
44. Kehe K, Balszuweit F, Elmmer J, Kreppel H, Jochum M, Tierman H. (2008). Sulfur mustard research-strategies for the development of improved medical therapy. Eplasty 8:e32.
45. Kehe K, Reisinger H, Szinicz L. (2000). Sulfur mustard induces apoptosis and necrosis in SCL II cells in vitro. J Appl Toxicol 20:S81-S86.
46. Kehe K, Szinicz L. (2005). Medical aspects of sulfur mustard poisoning. Toxicology 214:198-209.
47. Keyhani A, Eslami MB, Razavimanesh H. (2007). The short-term effect of mustard gas on the serum immunoglobulin levels. Iran J Allergy Asthma Immunol 6:15-19.
48. Khateri S, Ghanei M, Keshavarz S, Soroush M, Haines D. (2003). Incidence of lung, eye, and skin lesions as late complications in 34,000 Iranians with wartime exposure to mustard agent. J Occup Environ Med 45:1136-1143.
49. Khateri S, Organization of Veterans Affairs. (2001). Statistical Views on Late Complications of Chemical Weapons on Iranian CW Victims. The ASA Newsletter.
50. Kinsey VE, Grant WM. (1946). Determination of the rate of disappearance of mustard gas and mustard intermediates in corneal tissue. J Clin Invest 25:776-779.
51. Le HQ, Knudsen SJ. (2006). Exposure to a First World War blistering agent. J Emerg Med 23:296-299.
52. Lefkowitz LJ, Smith WJ. (2002). Sulfur mustard-induced ara-chidonic acid release is mediated by phospholipase D in human keratinocytes. Biochem Biophys Res Commun 295:1062-1067.
53. Lindsay CD, Rice P. (1996). Assessment of the biochemical effects of percutaneous exposure of sulfur mustard in an in vitro human skin system. Hum Exp Toxicol 15:237-244.
54. Liu DK, Wannemacher RW, Snider TH, Hayes TL. (1999). Efficacy of the topical skin protectant in advanced development. J Appl Toxicol 19:S40-S54.
55. Mahmoudi M, Hefazi M, Rastin M, Balali-Mood M. (2005). Long-term hematological and immunological complications of sulfur mustard poisoning in Iranian veterans. Int Immunopharmacol 5:1479-1485.
56. Mann I. (1944). A study of eighty-four cases of delayed mustard gas keratitis fitted with contact lenses. Br J Ophthalmol 28:441-447.
57. Meisenberg BR, Melaragno AJ, Monroy RL. (1993). Granulocyte colony stimulating factor (G-CSF) for mustard-induced bone marrow suppression. Mil Med 158:470-474.
58. Merat S, Perez JP, Ruttimann M, Bordier E, Lienhard A, Lenoir B, Pats B. (2003). [Acute poisoning by chemical warfare agent: sulfur mustard]. Ann Fr Anesth Reanim 22:108-118.
59. Meier HL, Millard C, Moser J. (2000). Poly(ADP-ribose) polymer-ase inhibitors regulate the mechanism of sulfur mustard-initiated cell death in human lymphocytes. J Appl Toxicol 20:S93-S100.
60. Mellor SG, Rice P, Cooper GJ. (1991). Vesicant burns. Br J Plast Surg 44:434-437.
61. Mol ME, de Ruit V, Kluivers AW. (1991). Effects of nicotinamide on biochemical changes and microblistering induced by sulfur mustard in human skin organ cultures. Toxicol Appl Pharmacol 107:439-449.
62. Momeni AZ, Aminjavaheri M. (1994). Skin manifestations of mustard gas in a group of 14 children and teenagers: a clinical study. Int J Dermatol 33:184-187.
63. Momeni AZ, Enshaeih S, Meghdadi M, Amindjavaheri M. (1992). Skin manifestations of mustard gas. A clinical study of 535 patients exposed to mustard gas. Arch Dermatol 128:775-780.
64. Moser J, Meier HL. (2000). Comparison of cell size in sulfur mustard-induced death of keratinocytes and lymphocytes. J Appl Toxicol 20:S23-S30.
65. Munro NB, Talmage SS, Griffin GD, Waters LC, Watson AP, King JF, Hauschild V. (1959). The sources, fate, and toxicity of chemical warfare agent degradation products. Environ Health Perspect 43:933-974.
66. Naghii MR. (2002). Sulfur mustard intoxication, oxidative stress, and antioxidants. Mil Med 167:573-575.
67. Nishimoto Y, Yamakido M, Shigenobu T, Yukutake M, Matsusaka S. (1986). [Cancer of the respiratory tract observed in workers having retired from a poison gas factory]. Gan To Kagaku Ryoho 13:1144-1148.
68. Noort D, Benschop HP, Black RM. (2002). Biomonitoring of exposure to chemical warfare agents: a review. Toxicol Appl Pharmacol 184:116-126.
69. Norman JE Jr. (1975). Lung cancer mortality in World War I veterans with mustard-gas injury: 1919-1965. J Natl Cancer Inst 54:311-317.
70. Notingher I, Imhof RE. (2004). Mid-infrared in vivo depth-profiling of topical chemicals on skin. Skin Res Technol 10:113-121.
71. Panahi Y, Motiei-Langroudi R, Alaeddini F, Naghizadeh MM, Aslani J, Ghanei M. (2008). Furosemide inhalation in dyspnea of mustard gas-exposed patients: a triple-blind randomized study. Inhal Toxicol 20:873-877.
72. Papirmeister B, Feister AJ, Robinson SI, Ford RD. (1991). Medical Defense against Mustard Gas. Boca Raton, FL: CRC Press.
73. Papirmeister B, Gross CL, Meier HL, Petrali JP, Johnson JB. (1985). Molecular basis for mustard-induced vesication. Fundam Appl Toxicol 5:S134-S149.
74. Pleyer U, Sherif Z, Baatz H, Hartmann C. (1999). Delayed mustard gas keratopathy: clinical findings and confocal microscopy. Am J Ophthalmol 128:506-507.
75. Rappeneau S, Baeza-Squiban A, Marano F, Calvet J. (2000). Efficient protection of human bronchial epithelial cells against sulfur and nitrogen mustard cytotoxicity using drug combinations. Toxicol Sci 58:153-160.
76. Ray P, Chakrabarti AK, Broomfield CA, Ray R. (2002). Sulfur mustard-stimulated protease: a target for antivesicant drugs. J Appl Toxicol 22:139-140.
77. Requena L, Requena C, Sanchez M, Jaqueti G, Aguilar A, Sanchez-Yus E, Hernandez-Moro B. (1988). Chemical warfare. Cutaneous lesions from mustard gas. J Am Acad Dermatol 19:529-536.
78. Riazi A, Jadidi K, Naderi M, Karimi A, Babaei, M. (2004). Refractive errors as a late complication in sulfur mustard war victims. Mil Med 6:13-18.
79. Richter MN, Wachtlin J, Bechrakis NE, Hoffmann F. (2006). Keratoplasty after mustard gas injury: clinical outcome and histology. Cornea 25:467-469.
80. Rosenthal DS, Simbulan-Rosenthal CM, Iyer S, Spoonde A, Smith W, Ray R, Smulson ME. (1998). Sulfur mustard induces markers of terminal differentiation and apoptosis in kerati-nocytes via a Ca2+-calmodulin and caspase-dependent pathway. J Invest Dermatol 111:64-71.
81. Ruhl CM, Park SJ, Danisa O, Morgan RF, Papirmeister B, Sidell FR, Edlich RF, Anthony LS, Himel HN. (1994). A serious skin sulfur mustard burn from an artillery shell. J Emerg Med 12:159-166.
82. Safaei A, Saluti R, Kumar P V. (2001). Conjunctival dysplasia in soldiers exposed to mustard gas during the Iraq-Iran war: scrape cytology. Acta Cytol 45:909-913.
83. Safarinejad MR, Moosavi SA, Montazeri B. (2001). Ocular injuries caused by mustard gas: diagnosis, treatment, and medical defense. Mil Med 166:67-70.
84. Schnurr PP, Ford JD, Friedman MJ, Green BL, Dain BJ, Sengupta A. (2000). Predictors and outcomes of posttraumatic stress disorder in World War II veterans exposed to mustard gas. J Consult Clin Psychol 68:258-268.
85. Schnurr PP, Friedman MJ, Green BL. (1996). Post-traumatic stress disorder among World War II mustard gas test participants. Mil Med 161:131-136.
86. Shakil FA, Kuramoto A, Yamakido M, Nishimoto Y, Kamada N. (1993). Cytogenetic abnormalities of hematopoietic tissue in retired workers of the Ohkunojima poison gas factory. Hiroshima J Med Sci 42:159-165.
87. Shohrati M, Aslani J, Eshraghi M, Alaedini F, Ghanei M. (2008). Therapeutics effect of N-acetyl cysteine on mustard gas exposed patients: evaluating clinical aspect in patients with impaired pulmonary function test. Respir Med 102:443-448.
88. Shohrati M, Davoudi SM, Keshavarz S, Sadr B, Tajik A. (2007). Cetirizine, doxepine, and hydroxyzine in the treatment of pruritus due to sulfur mustard: a randomized clinical trial. Cutan Ocul Toxicol 26:249-255.
89. Shohrati M, Peyman M, Peyman A, Davoudi M, Ghanei M. (2007). Cutaneous and ocular late complications of sulfur mustard in Iranian veterans. Cutan Ocul Toxicol 26:73-81.
90. Sidell FR, Urbanetti JS, Smith WJ, Hurst CG. (1999). Vesicants. In Sidell FR, Takafuti ET, Franz DR, eds. Medical Aspects of Clinical and Biological Warfare. Washington, DC: Office of the Surgeon General, pp. 197-228.
91. Smith WJ, Gross CL. (2002). Sulfur mustard medical countermeasures in a nuclear environment. Mil Med 167:101-102.
92. Solberg Y, Alcalay M, Belkin M. (1997). Ocular injury by mustard gas. Surv. Ophthalmol., 41:461-466.
93. Somani SM, Babu SR. (1989). Toxicodynamics of sulfur mustard. Int J Clin Pharmacol Ther Toxicol 27:419-435.
94. Stallard HB. (1940). An improvised eye-irrigator for use in the field. Br J Ophthalmol 24:53-57.
95. Stone WL, Qui M, Smith M. (2003). Lipopolysaccharide enhances the cytotoxicity of 2-chloroethyl ethyl sulfide. BMC Cell Biol 4:1.
96. Sun J, Wang YX, Sun MJ. (1999). Apoptosis and necrosis induced by sulfur mustard in Hela cells. Zhongguo Yao Li Xue Bao 20:445-448.
97. Szinicz L. (2005). History of chemical and biological warfare agents. Toxicology 214:167-181.
98. Thomsen AB, Eriksen J, Smidt-Nielsen K. (1998). Chronic neuropathic symptoms after exposure to mustard gas: a long-term investigation. J Am Acad Dermatol 39:187-190.
99. van der Schans GP, Noort D, Mars-Groenendijk RH, Fidder A, Chau LF, de Jong LP, Benschop HP. (2002). Immunochemical detection of sulfur mustard adducts with keratins in the stratum corneum of human skin. Chem Res Toxicol 15:21-25.
100. Vidan A, Luria S, Eisenkraft A, Hourvitz A. (2002). Ocular injuries following sulfur mustard exposure: clinical characteristics and treatment. Isr Med Assoc J 4:577-578.
101. Wang GQ, Xia ZF. (2007). Tissue injury by hot fluid containing nitrogen mustard. Burns 33:923-926.
102. Watson AP, Griffin GD. (1992). Toxicity of vesicant agents scheduled for destruction by the Chemical Stockpile Disposal Program. Environ Health Perspect 98:259-280.
103. Willems JL. (1989). Clinical management of mustard gas casualties. Medicinae Militaris (Belgicae) 3:161.
104. Withman LB. (1918). Military ophthalmology.
105. Zhang Z, Peters BP, Monteiro-Riviere NA. (1995). Assessment of sulfur mustard interaction with basement membrane components. Cell Biol Toxicol 11:89-101.
106. Zikler T. (2005). Medical management of incidents with chemical warfare agents. Toxicology 214:221-231.